alpha-aminopyridine has been researched along with gefitinib in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Downing, JR | 1 |
| Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
| Koizumi, H; Li, Q; Matsumoto, K; Mukaida, N; Nakagawa, T; Nakamura, T; Nishioka, Y; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Eisenstein, M | 1 |
| Cao, Z; Chen, Y; Guo, W; Hu, H; Li, B; Liu, J; Pang, J; Song, M; Song, X; Wang, C; Wang, J; Wang, M; Xing, Y; Yang, H; Yang, J; Yang, P; Zhang, T; Zhang, Z | 1 |
1 review(s) available for alpha-aminopyridine and gefitinib
| Article | Year |
|---|---|
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
8 other study(ies) available for alpha-aminopyridine and gefitinib
| Article | Year |
|---|---|
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |
Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.
Topics: Aminopyridines; Animals; ErbB Receptors; Gefitinib; Inflammation; Mice; Morpholines; Pulmonary Fibrosis; Pyridines; Pyrimidines; Silicosis | 2022 |